A major challenge in precision oncology is to detect targetable cancer vulnerabilities in individual patients. Modeling high-throughput omics data in biological networks allows identifying key ...
Understanding biological systems requires methods that extract interpretable insights from omics data. Networks offer a natural abstraction by representing molecules as vertices and their interactions ...
Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results